Dr. Prasanna Jagannathan is an Associate Professor of Medicine and of Microbiology and Immunology at Stanford University with a research program in human immunology of malaria and clinical trials of immune modulatory interventions. After completing a B.A. in Religious Studies at the University of California, Berkeley, he taught High School Science through Teach for America in Los Angeles, CA before obtaining his M.D. from Harvard Medical School. During medical school, he was a Howard Hughes Medical Institute/NIH Research Scholar in the Laboratory of Dr. Mark Connors studying correlates of immune control of HIV.  He completed Internal Medicine training at the University of California, San Francisco (UCSF), and served as Chief Resident, before completing training in Infectious Diseases at UCSF. He obtained a post-doctoral fellowship from the Burroughs Wellcome Fund/American Society of Tropical Medicine and Hygiene to study naturally acquired immunity to malaria, and was mentored in pediatric immunology under Dr. Margaret Feeney, and in malaria epidemiology and clinical trials under Dr. Grant Dorsey.  He obtained a K23 physician-scientist career development award from NIAID to study the impact of antimalarial chemoprevention on parasite-induced immunoregulatory networks, and in 2017, was recruited to a tenure-track faculty position at Stanford University in the Department of Medicine, Division of Infectious Diseases and Geographic Medicine.  At Stanford, his group has been conducting detailed longitudinal cohort studies in children and pregnant women in order to define how repeated malaria shapes both the innate and adaptive cellular immune response.  He also leads clinical trials of antimalarial chemoprevention in children, and studies how malaria control interventions such as chemoprevention and vector control shape the acquisition and/or maintenance of protective immunity to malaria. During the SARS-CoV-2 pandemic, he also led clinical trials of immune modulatory interventions for SARS-CoV-2 infection at Stanford and with the NIH-sponsored ACTIV-2 consortium.